📰 BloombergBloombergCodex · 实盘不做把握 3/10
北京时间·🕒 发布 00:31:52时区推断·⟳ 抓取 00:40:39·⚡ 决策 08-06 00:42:26 +1m47s·82.8 天前
Attovia Therapeutics 美国IPO首日开盘较发行价上涨24%
这是一条IPO首日交易表现报道，核心新增信息是股价已经较发行价上涨约24%，不是新的订单、临床、监管或业绩催化。
📄 原文Bloomberg↗ 原文
Attovia Therapeutics Inc. shares jumped 24% in its trading debut, after the early-stage drug developer focused on immun…
不做 Attovia Therapeutics（ATTO.US）
IPO首日已经上涨约24%，当前信号是市场反应播报而非新增基本面催化；早期管线无短期收入传导，追涨无明确edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-05 · 扩散 medium · price-in 风险 high ↗
关键理由
- 这是一条IPO首日交易表现报道，核心新增信息是股价已经较发行价上涨约24%，不是新的订单、临床、监管或业绩催化。
- 公司仍处早期研发阶段，文中披露的管线为Phase 1及计划启动试验，短线无法量化出新增收入或利润传导。
主要风险
- IPO首日波动和流动性不稳定，报道到达时主要反应已经发生，追涨缺少可回测基本面edge。
原文全文
展开原文 · 2,057 字
Attovia Therapeutics Inc. shares jumped 24% in its trading debut, after the early-stage drug developer focused on immune system diseases raised $289 million in a US initial public offering.
The company’s shares opened at $21 each as of 12:18 p.m. in New York, above its IPO price of $17 apiece. The trading gives the company a market value of nearly $904 million, based on the outstanding shares in its filings.
Attovia is developing drugs using a technology platform and patents licensed from Alamar Biosciences Inc., a maker of medical devices focused on studying proteins and disease detection. Alamar set up Attovia as a separate company in 2023 and remains an investor. Alamar raised $219.9 million in an April IPO, and the shares have climbed nearly 70% since its debut.
Read More: Medical Device Maker Alamar Bio Jumps 29% After Upsized IPO
Attovia has one drug targeting interleukin-31 that has completed dosing in a Phase 1 trial and another targeting interleukin-13 that is expected to start trials in the first half of next year.
IPOs of biotechnology and pharmaceutical companies have been among the strongest performing new listings this year, led by pattern hair loss-focused Veradermics Inc.’s more than 550% increase since its debut in February and a 173% gain in the shares of blood disorder specialist Hemab Therapeutics Inc. following its debut in May.
Frazier Life Sciences was expected to have a 13% stake in Attovia following the offering, down from 21%, Attovia’s filings show. VenBio has 8.8%, falling from 15%, and an affiliate of Goldman Sachs Group Inc. has 5.7%, down from 9.3%, according to the filings.
Attovia’s IPO was led by Morgan Stanley, Leerink Partners, Citigroup Inc. and Royal Bank of Canada. The shares trade on the Nasdaq Global Market under the symbol ATTO.
For the latest news on equity capital markets activity in the US, Canada and Latin America, terminal users can follow the channel or visit NI BFWECMUS. To subscribe to ECM Watch, Bloomberg’s daily roundup of news from around the region, click here.
The company’s shares opened at $21 each as of 12:18 p.m. in New York, above its IPO price of $17 apiece. The trading gives the company a market value of nearly $904 million, based on the outstanding shares in its filings.
Attovia is developing drugs using a technology platform and patents licensed from Alamar Biosciences Inc., a maker of medical devices focused on studying proteins and disease detection. Alamar set up Attovia as a separate company in 2023 and remains an investor. Alamar raised $219.9 million in an April IPO, and the shares have climbed nearly 70% since its debut.
Read More: Medical Device Maker Alamar Bio Jumps 29% After Upsized IPO
Attovia has one drug targeting interleukin-31 that has completed dosing in a Phase 1 trial and another targeting interleukin-13 that is expected to start trials in the first half of next year.
IPOs of biotechnology and pharmaceutical companies have been among the strongest performing new listings this year, led by pattern hair loss-focused Veradermics Inc.’s more than 550% increase since its debut in February and a 173% gain in the shares of blood disorder specialist Hemab Therapeutics Inc. following its debut in May.
Frazier Life Sciences was expected to have a 13% stake in Attovia following the offering, down from 21%, Attovia’s filings show. VenBio has 8.8%, falling from 15%, and an affiliate of Goldman Sachs Group Inc. has 5.7%, down from 9.3%, according to the filings.
Attovia’s IPO was led by Morgan Stanley, Leerink Partners, Citigroup Inc. and Royal Bank of Canada. The shares trade on the Nasdaq Global Market under the symbol ATTO.
For the latest news on equity capital markets activity in the US, Canada and Latin America, terminal users can follow the channel or visit NI BFWECMUS. To subscribe to ECM Watch, Bloomberg’s daily roundup of news from around the region, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。